Jemincare Group announces increasing R&D in Pudong

China's pharmaceutical company Jemincare Group announced that it will increase research and development (R&D) at the Zhangjiang Pharma Valley in Pudong New Area, East China's Shanghai.

As one of the country's most distinctive and dynamic areas for innovation, Pudong has gathered a slew of high-level biomedicine enterprises.

Jemincare Group, headquartered in Nanchang, Jiangxi province, was rated 428th among the top 500 Chinese private enterprises last year. The group has made remarkable achievements in R&D since it established its R&D center at the Zhangjiang Pharma Valley in 2018.

Jemincare's R&D center now has a professional team and focuses on the development of innovative medicines, enabling them tap into the global market, according to Cui Haifeng, Jemincare's chief science officer.

Cui added that currently, the group is beefing up efforts to expand international cooperation to boost innovation.

Earlier this year, Pudong released an array of supportive measures to promote the development of the biomedicine industry from 2022 to 2024, aiming to build a world-class biomedicine industrial cluster in the area.

Biomedicine is among Shanghai's three leading industries, and one of Pudong's six core industries. The local government plans to make Pudong a national leader in biomedical research and development, as well as the cradle of new and innovative medicine.

Zhangjiang Pharma Valley in Pudong New Area, East China's Shanghai, is a hub supporting startups and pioneering projects of established firms. It has incubated some 380 biopharma companies and seen over 10 incubated enterprises go public. [Photo provided to chinadaily.com.cn]